Posted September 1, 2026
Quiet day for California Board of Pharmacy activity. The bigger story right now is 340B, where drug manufacturers pushed back against the program on three separate fronts this week, and mostly lost.
Manufacturers can’t switch to a rebate model without HRSA’s sign-off
The D.C. Circuit Court of Appeals sided with the federal government in a long-running dispute over how 340B discounts get delivered. Manufacturers that wanted to move from upfront discounts to a rebate model needed HRSA approval first, and didn’t have it. Read more at Frier Levitt →
HRSA is asking 340B providers about their contract pharmacy agreements
Sanofi has requested that certain 340B contract pharmacy agreements be disclosed, and HRSA has reached out to the providers involved. If your pharmacy holds a 340B contract pharmacy relationship, this is worth watching for what HRSA does next. Read more at 340B Report →
A federal judge dismissed AstraZeneca’s challenge to Colorado’s 340B law
It isn’t California law, but it’s the same fight (manufacturers trying to limit where 340B drugs can be dispensed) playing out state by state, and it’s another loss for the manufacturer side. Read more at 340B Report →
CMS is being pushed to drop a proposed cut to 340B payments
Hospital groups want CMS to abandon a proposed reduction to 340B payments under the outpatient payment rule, while two industry groups are backing the cut. The comment period is still open. Read more at 340B Report →
A federal 340B reform bill is drawing mixed reactions
Senator Bill Cassidy’s draft 340B reform legislation is getting pushback from providers over some of its proposed changes. Early stage, but a bill worth watching if you’re tracking federal reform. Read more at 340B Report →
Why isn’t a PBM’s own biosimilar showing up on its own formulary?
A recent analysis found that PBM-affiliated private-label biosimilars often aren’t covered on their own corporate siblings’ Medicare Part D formularies, even where you’d expect a built-in advantage. Useful context if you’ve ever wondered why. Read more at Drug Channels →
This update is general information about developments in pharmacy law and regulation. It is not legal advice, it does not create an attorney-client relationship, and it should not be relied on as a substitute for advice about your own situation. Prior results do not guarantee a similar outcome. If you have a specific question about your pharmacy, call or write and we will talk about it properly.
Law Office of Bhavesh Desai | Bhavesh Desai, Pharm.D., Esq.
18085 Watson Way, Yorba Linda, CA 92886 | (909) 618-7299
Leave a Reply